In Re Namenda Direct Purchaser Antitrust Litigation

  1. June 15, 2020

    $88M Cut From Requested $157.5M Atty Fee In Namenda Deal

    A Manhattan federal judge on Monday slashed nearly $88 million from a $157.5 million fee award requested by Garwin Gerstein & Fisher LLP and five other firms for guiding wholesalers of the Alzheimer's drug Namenda to a $750 million antitrust settlement with a unit of Allergan PLC.

  2. May 27, 2020

    $750M Namenda Deal OK'd But 21% Atty Fee Request In Doubt

    A Manhattan federal judge on Wednesday approved a landmark $750 million settlement over allegations that an Allergan PLC subsidiary thwarted generic competition for its Alzheimer's drug Namenda, but cast doubt on awarding $157 million in attorney fees, calling the figure "astronomically large."

  3. March 13, 2020

    Namenda Buyers' Attys Seek $212M From Allergan Deal

    The legal team that steered drug wholesalers to a record-breaking $750 million deal with Allergan PLC over claims its subsidiary thwarted generic competition has requested a $212 million cut of the pot to cover its fees and expenses.

  4. October 29, 2019

    ​​​​​​​Allergan's $750M Deal Among Pharma's Top Antitrust Payouts

    A $750 million settlement this week by Allergan to avert an antitrust trial involving Alzheimer's drug Namenda is among the most eye-popping sums ever shelled out by a drugmaker for allegedly thwarting generic competition.

  5. October 28, 2019

    Allergan Paying $750M To End Namenda Antitrust Fight

    Allergan PLC said Monday that it has reached a $750 million deal to get its Forest Laboratories unit out from under a massive antitrust suit in New York federal court that accuses the drugmaker of anti-competitive conduct to keep generic versions of Namenda off pharmacy shelves.

  6. June 04, 2019

    Forest Labs Scorched By 'Displeased' Judge After Fire Drill

    After a fire drill delay, a Manhattan federal judge fumed at Forest Laboratories LLC on Tuesday for failing to disclose a memo earlier in an antitrust suit alleging that the drugmaker blocked generic alternatives to its Namenda Alzheimer's treatment, saying she was "very displeased with Forest."

  7. September 26, 2017

    Forest Labs Must Produce Mylan Docs In Antitrust Suit

    A New York magistrate judge on Monday ordered Forest Laboratories LLC to produce documents previously withheld in an antitrust suit alleging that the drugmaker blocked generic alternatives to its Namenda Alzheimer's treatment.

  8. July 20, 2017

    Namenda Buyers' Experts Should Stay, Judge Says

    A New York magistrate judge on Thursday recommended allowing the testimony of two experts in an antitrust suit alleging Forest Laboratories LLC blocked generic alternatives to its Namenda Alzheimer's treatment.

  9. July 06, 2017

    Namenda Wholesalers Fire Back At Teva's Bid To DQ Expert

    Drug wholesalers denounced Teva Pharmaceuticals USA's attempt to disqualify one of its former executives as an expert in their antitrust suit alleging Forest Laboratories LLC blocked generic alternatives to its Namenda Alzheimer's treatment, telling a New York federal judge Wednesday that nonparty Teva could provide no evidence its confidential information would be compromised.

  10. July 03, 2017

    Teva Wants Ex-Exec DQ'd As Expert In Namenda Buyers' Suit

    Teva Pharmaceuticals USA has urged a New York federal judge to disqualify one of its former executives as an expert in an antitrust suit alleging Forest Laboratories LLC blocked generic alternatives to its Namenda Alzheimer's treatment, saying the former employee has been exposed to confidential information related to Teva.